Stemline Therapeutics, Inc. (STML) Financial Statements (2024 and earlier)
Company Profile
Business Address |
750 LEXINGTON AVENUE NEW YORK, NY 10022 |
State of Incorp. | DE |
Fiscal Year End | December 31 |
Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
3/31/2020 MRQ | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | |||
---|---|---|---|---|---|---|---|---|---|
ASSETS | |||||||||
Current Assets | |||||||||
Cash, cash equivalents, and short-term investments | 164,431 | 60,106 | 51,720 | 46,879 | 46,039 | 53,983 | |||
Cash and cash equivalents | 13,562 | 9,444 | 4,795 | 10,316 | 13,376 | 25,007 | |||
Short-term investments | 150,869 | 50,662 | 46,925 | 36,563 | 32,663 | 28,976 | |||
Receivables | 15,120 | ||||||||
Inventory, net of allowances, customer advances and progress billings | 1,151 | ||||||||
Inventory | 1,151 | ||||||||
Prepaid expense | 140 | 69 | 44 | 48 | 52 | 47 | |||
Deferred costs | 144 | ||||||||
Deposits current assets | 556 | 189 | 106 | 106 | |||||
Other undisclosed current assets | 3,763 | 2,695 | 281 | 243 | 494 | 1,484 | |||
Total current assets: | 185,161 | 63,059 | 52,189 | 47,170 | 46,691 | 55,620 | |||
Noncurrent Assets | |||||||||
Property, plant and equipment | 191 | 222 | 137 | 23 | 96 | 230 | |||
Long-term investments and receivables | 14,468 | 20,715 | 51,429 | 4,645 | |||||
Long-term investments | 14,468 | 20,715 | 51,429 | 4,645 | |||||
Other noncurrent assets | 309 | 212 | 212 | 212 | |||||
Other undisclosed noncurrent assets | 1,318 | ||||||||
Total noncurrent assets: | 1,818 | 435 | 14,817 | 20,949 | 51,524 | 4,875 | |||
TOTAL ASSETS: | 186,979 | 63,494 | 67,006 | 68,119 | 98,216 | 60,495 | |||
LIABILITIES AND EQUITY | |||||||||
Liabilities | |||||||||
Current Liabilities | |||||||||
Accounts payable and accrued liabilities, including: | 21,952 | 21,153 | 19,742 | 9,285 | 9,455 | 6,171 | |||
Employee-related liabilities | 5,599 | 5,515 | 2,940 | 1,975 | 1,697 | ||||
Accrued liabilities | 421 | 687 | 1,961 | 517 | 9,455 | 4,474 | |||
Other undisclosed accounts payable and accrued liabilities | 15,933 | 14,951 | 14,841 | 6,793 | |||||
Deferred revenue and credits | ✕ | ✕ | ✕ | 898 | 486 | ||||
Other liabilities | 10 | 66 | 97 | 71 | |||||
Other undisclosed current liabilities | 1,170 | (2,182) | |||||||
Total current liabilities: | 23,132 | 21,219 | 19,839 | 10,254 | 9,455 | 4,474 | |||
Noncurrent Liabilities | |||||||||
Liabilities, other than long-term debt | 4 | 73 | 97 | 142 | 648 | 608 | |||
Deferred revenue and credits | ✕ | ✕ | ✕ | 617 | 608 | ||||
Other liabilities | 4 | 73 | 97 | 142 | 31 | ||||
Other undisclosed noncurrent liabilities | 226 | ||||||||
Total noncurrent liabilities: | 231 | 73 | 97 | 142 | 648 | 608 | |||
Total liabilities: | 23,363 | 21,292 | 19,936 | 10,396 | 10,104 | 5,082 | |||
Equity | |||||||||
Equity, attributable to parent | 163,616 | 42,202 | 47,070 | 57,723 | 88,112 | 55,413 | |||
Common stock | 5 | 3 | 3 | 2 | 2 | 1 | |||
Additional paid in capital | 529,488 | 331,343 | 251,490 | 193,564 | 185,703 | 115,605 | |||
Accumulated other comprehensive income (loss) | 28 | (57) | (146) | (100) | (154) | 3 | |||
Accumulated deficit | (365,905) | (289,088) | (204,276) | (135,743) | (97,440) | (60,196) | |||
Total equity: | 163,616 | 42,202 | 47,070 | 57,723 | 88,112 | 55,413 | |||
TOTAL LIABILITIES AND EQUITY: | 186,979 | 63,494 | 67,006 | 68,119 | 98,216 | 60,495 |
Income Statement (P&L) ($ in thousands)
3/31/2020 TTM | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
---|---|---|---|---|---|---|---|---|
Revenues | 500 | 898 | 1,041 | 654 | 335 | |||
Revenue, net | ✕ | ✕ | ✕ | 898 | 1,041 | 654 | 335 | |
Cost of revenue (Cost of Goods and Services Sold) | (4,893) | |||||||
Gross profit: | (4,893) | 500 | 898 | 1,041 | 654 | 335 | ||
Operating expenses | (117,571) | (86,787) | (69,457) | (39,927) | (38,288) | (29,325) | ||
Other undisclosed operating income | 43,217 | |||||||
Operating loss: | (79,248) | (86,287) | (68,558) | (38,885) | (37,633) | (28,990) | ||
Nonoperating income | 2,491 | 1,263 | 730 | 557 | 388 | 156 | ||
Investment income, nonoperating | 2,538 | 1,271 | 736 | 546 | 386 | 153 | ||
Interest and debt expense | (35) | (1) | ||||||
Loss from continuing operations before income taxes: | (76,792) | (85,024) | (67,828) | (38,328) | (37,245) | (28,833) | ||
Income tax benefit | 26 | 15,656 | 3,402 | 25 | 21,390 | 16,568 | ||
Loss from continuing operations: | (76,766) | (69,369) | (64,426) | (38,303) | (15,856) | (12,265) | ||
Loss before gain (loss) on sale of properties: | (76,766) | (69,369) | (64,426) | (38,303) | (15,856) | (12,265) | ||
Other undisclosed net loss | (51) | (15,656) | (3,402) | |||||
Net loss attributable to parent: | (76,817) | (85,024) | (67,828) | (38,303) | (15,856) | (12,265) | ||
Other undisclosed net loss available to common stockholders, basic | (21,388) | (16,565) | ||||||
Net loss available to common stockholders, diluted: | (76,817) | (85,024) | (67,828) | (38,303) | (37,244) | (28,830) |
Comprehensive Income ($ in thousands)
3/31/2020 TTM | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
---|---|---|---|---|---|---|---|---|
Net loss: | (76,817) | (85,024) | (67,828) | (38,303) | (15,856) | (12,265) | ||
Comprehensive loss: | (76,817) | (85,024) | (67,828) | (38,303) | (15,856) | (12,265) | ||
Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 85 | 89 | (46) | 54 | (21,545) | (16,518) | ||
Comprehensive loss, net of tax, attributable to parent: | (76,732) | (84,935) | (67,875) | (38,249) | (37,401) | (28,783) |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.